Preclinical Triple-Humanized genO-hCD28/hPD-1/hPD-L1 Mouse Model

The genO‑hCD28 mouse enables the in vivo efficacy and safety assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

genO‑hCD3ε/hCD28 immunocompetent mice enable the in vivo efficacy and safety assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

The genO‑hPD‑1/hICOS mouse enables the in vivo efficacy assessment of compounds targeting the human immune checkpoint PD-1 and/or ICOS in fully immunocompetent mice.

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD3 and CD28 compounds.

‍

Double-humanized genO-panhCD3/hPD-1 immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD3 and PD-1 compounds.

The humanized hPD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

The genO-MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form infiltrated tumors in immunocompetent mice.

The genO-MC38-hEpCAM-LZ clonal cell line expresses human EpCAM (NCBI GeneID: 4072), and an optimized dual fusion reporter, luciferase-ZsGreen (LZ)

The genO‑MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.

The genO-MC38-hPD-L1-hFAP-LZ clonal cell line expresses human PD-L1, human FAP and an optimized dual fusion reporter, luciferase-ZsGreen (LZ)

The genO-MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.